Drug Search Results

BBO8520

Alternative Names: BBO8520, BBO-8520
Latest Update: 2025-04-01
Latest Update Note: News Article

Product Description

Mechanisms of Action: KRAS G12C Inhibitor

Novel Mechanism: No

Modality: Small Molecule

Route of Administration: Oral

FDA Designation: Fast Track - Non-Small-Cell Lung Cancer *

Approval Status: Not Approved

Approved Countries: None

Approved Indications: None

Known Adverse Events: None

Company: BridgeBio
Company Location: PALO ALTO CA 94301
Company CEO: Neil Kumar
Additional Commercial Interests: None

Clinical Description

Map of Global Clinical Trials for BBO8520

Countries in Clinic: Australia, United States

Active Clinical Trial Count: 1

Highest Development Phases

Phase 1: Non-Small-Cell Lung Cancer

Trial	Phase	Trial Status	Disease	Primary Completion Date	Probability of Success
TBBO8520-101	P1	Recruiting	Non-Small-Cell Lung Cancer	2027-08-01

Recent News Events

Date	Type	Title
04/01/2025	News Article	BBOT Announces First Patient Dosed with BBO-11818, a PanKRAS Dual Inhibitor, in the Phase 1 KONQUER-101 Trial for Advanced Solid Tumors
02/28/2025	News Article	BridgeBio Oncology Therapeutics (BBOT) and Helix Acquisition Corp. II Announce Business Combination Agreement to Create Publicly Listed Biotechnology Company Advancing a Pipeline of RAS and PI3Kα-Targeting Medicines
01/09/2025	News Article	BridgeBio Oncology Therapeutics (BBOT) Granted U.S. FDA Fast Track Designation for BBO-8520 for KRASG12C-Mutated Metastatic Non-Small Cell Lung Cancer
12/09/2024	News Article	BBO-8520 Preclinical Data Published in Cancer Discovery Supports the Potential for the First-in-Class Molecule to Provide Therapeutic Benefit in KRASG12C Mutant Tumors

Did PRYZM just deliver the data you were looking for?
Did you try our Excel download too?

Now that you've used PRYZM, we hope you're able to see for yourself that it was designed and developed by people who actually use this data for a living. By applying next-generation technology for aggregating and curating this info across multiple key sources PRYZM delivering the latest information at your fingertips just the way you need it and with industry leading speed and cost effectiveness.

Our subscribers enjoy unlimited searches and receive this data on their own secure instance so they can overlay any additional internal/proprietary data on top of the search results and blend that data with real-time industry intel from PRYZM. Discover how you can continue to uncover the competitive landscape and drive strategy.

Suggestions